Advanced Hematologic Malignancy
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Foghorn TherapeuticsFHD-286
Foghorn TherapeuticsFHD-286
Clinical Trials (2)
Total enrollment: 164 patients across 2 trials
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Start: Sep 2026Est. completion: Jan 202920 patients
Phase 2Not Yet Recruiting
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Start: Jun 2021Est. completion: Jun 2027144 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.